Compare DexCom, Inc. (DXCM) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs RLX Technology Inc — how do they compare? DexCom, Inc. trades at $90.76 (market cap $33.79B), while RLX Technology Inc trades at $2.02 (market cap $2.42B). The key difference: DexCom, Inc. is far larger — about 14× RLX Technology Inc's market cap, and RLX Technology Inc pays a 5.05% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | RLX | |
|---|---|---|
Market Cap | $33.79B | $2.42B |
Sector | Health | Technology |
52-Week High | $90.80 | $2.73 |
52-Week Low | $54.84 | $1.79 |
Enterprise Value | $33.24B | $1.04B |
Dividend Yield | — | 5.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
RLX Technology trades at $2.02, up 1.0% today, amid bearish technical signals and mixed fundamental performance. The stock shows strong profitability with 22.47% net margins and solid cash flow generation, though recent quarterly earnings have missed expectations. International expansion remains a key growth driver, with overseas revenue now exceeding 70% of total sales following the Totally Wicked acquisition.
While RLX maintains strong fundamentals and cash reserves, the bearish technical outlook and recent earnings misses create near-term uncertainty. The company's international growth strategy offers potential upside, but regulatory risks in the vaping industry and execution challenges pose significant headwinds for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
